Stem cell bioprocess engineering towards cGMP production and clinical applications |
| |
Authors: | Sébastien Sart Yves-Jacques Schneider Yan Li Spiros N Agathos |
| |
Institution: | 1. Department of Chemical and Biomedical Engineering, FAMU-FSU College of Engineering, Florida State University, 2525 Pottsdamer St, Tallahassee, FL, 32310, USA 2. Laboratory of Cellular Biochemistry, Institut des Sciences de la Vie, Université Catholique de Louvain, Place Croix du Sud, 4/5 box L7.07.03, 1348, Louvain-la-Neuve, Belgium 3. Laboratory of Bioengineering (GEBI), Institut des Sciences de la Vie and Earth and Life Institute, Université Catholique de Louvain, Place Croix du Sud, 2 box L7.05.19, 1348, Louvain-la-Neuve, Belgium
|
| |
Abstract: | Stem cells, including mesenchymal stem cells and pluripotent stem cells, are becoming an indispensable tool for various biomedical applications including drug discovery, disease modeling, and tissue engineering. Bioprocess engineering, targeting large scale production, provides a platform to generate a controlled microenvironment that could potentially recreate the stem cell niche to promote stem cell proliferation or lineage-specific differentiation. This survey aims at defining the characteristics of stem cell populations currently in use and the present-day limits in their applications for therapeutic purposes. Furthermore, a bioprocess engineering strategy based on bioreactors and 3-D cultures is discussed in order to achieve the improved stem cell yield, function, and safety required for production under current good manufacturing practices. |
| |
Keywords: | Stem cells Bioprocess engineering Bioreactor Differentiation Safety |
本文献已被 SpringerLink 等数据库收录! |
|